1. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.
- Author
-
Goldman RC, Frost DJ, Capobianco JO, Kadam S, Rasmussen RR, and Abad-Zapatero C
- Subjects
- Amino Acid Sequence, Animals, Aspartic Acid Endopeptidases chemistry, Aspartic Acid Endopeptidases genetics, Candida albicans genetics, Drug Design, Female, Glucans biosynthesis, Glucosyltransferases biosynthesis, Humans, Mice, Models, Biological, Models, Molecular, Molecular Sequence Data, Protease Inhibitors pharmacology, Virulence, Antifungal Agents pharmacology, Aspartic Acid Endopeptidases antagonists & inhibitors, Candida albicans chemistry, Candida albicans drug effects, Glucosyltransferases antagonists & inhibitors, Membrane Proteins, Schizosaccharomyces pombe Proteins, beta-Glucans
- Abstract
The incidence of severe, life-threatening fungal infections has increased dramatically over the last decade. Unfortunately, in practice the arsenal of antifungal drugs is limited to flucytosine, a few approved azoles, and polyenes, mainly amphotericin B. This situation is rather precarious in view of the extended spectrum of fungi causing severe disease in immunocompromised patients, development of resistance to some of the currently used agents, and the minimal fungicidal activity of the azoles. Although lagging behind the need for new antifungal agents, the study of fungal biochemistry, physiology, and genetics has undergone a resurgence to new heights of activity, thus providing a framework on which to build drug discovery programs in several new areas, two of which will be discussed in detail: the biology of Candida albicans secreted aspartyl protease with respect to inhibitor discovery, evaluation, and possible clinical utility; and the fungal cell wall beta-glucans with respect to the mechanism and regulation of synthesis and target sites for drug inhibition.
- Published
- 1995